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Abstract Introduction: The receptor for advanced glycation end products (RAGE) has been
implicated in the pathogenesis of RA through its ability to amplify inﬂammatory pathways.
Aims of the work: (1) To evaluate the levels of soluble receptors of advanced glycated end products
(sRAGE) as well as the gene variant among patients with rheumatoid arthritis (RA). (2) To assessAbbreviations: RA, rheumatoid arthritis; AGEs, advanced glycation
endproducts; sRAGE, soluble receptor for advanced glycation end
products; NF-jB, nuclear factor-kappaB; DAS28, disease activity
score; MS, morning stiffness; TJC, tender joint count; SJC, swollen
joint count; CRP, C-reactive protein; SNP, single nucleotide poly-
morphisms; G82S, glycine82serine gene polymorphism; HMGB1, high
mobility group box I or amphoterin; MMPs, matrix metallopro-
teinases.
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54 A. Mokbel et al.the association between the sRAGE level and the RAGE gene variants and to correlate the ﬁndings
with various clinical and laboratory data.
Patients and methods: All patients were fulﬁlling the criteria for RA described by the American
College of Rheumatology. In all patients assessment of disease activity was done by DAS28-
ESR. Soluble RAGE level was determined by enzymatic immunoassay. Molecular study of single
nucleotide polymorphisms (SNP) in the glycine82serine (G82S) of the RAGE gene was performed.
The data was collected and statistically analyzed.
Results: Serum levels of sRAGE were signiﬁcantly lower in RA patients than controls
(840.11 ± 230.32 pg/ml versus 1111.59 ± 143.20 pg/ml, p< 0.05). Genotyping of the RAGE gene
showed polymorphisms in the glycine82serine (G82S) allele which did not reach statistical signiﬁ-
cance between patients and controls.
The sRAGE levels were signiﬁcantly lower in RA patients with Sjogren’s syndrome and in those
with cardiac disease. Correlation analysis showed that the glycine82serine (G82S) allele is related
to MS, CRP and sRAGE in RA patients. Also, the G82S allele was more common in patients with
cardiac affection. Linear regression analysis detected CRP and gene polymorphism as signiﬁcant
predictors for sRAGE level.
Conclusion: The levels of sRAGE were signiﬁcantly lower in patients with RA and this reduction
was correlated with the disease activity parameters and glycine82serine gene polymorphism. The
sRAGE may be an important marker of disease activity. The correlation of sRAGE level and car-
diac disease can suggest that RAGE activity inﬂuences the co-development of joint and vascular
disease in rheumatoid arthritis patients. 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory disease
that leads to bone and cartilage destruction and extra-articular
complications, including atherosclerotic vascular disease and
premature mortality [1].
The receptor for advanced glycation end products (RAGE)
has been implicated in the pathogenesis of RA through its abil-
ity to amplify inﬂammatory pathways [2]. RAGE, is a member
of the immunoglobulin super family, encoded in the Class III
region of the major histocompatibility complex [3]. This mul-
tiligand receptor has one V type domain, two C type domains,
a transmembrane domain, and a cytoplasmic tail. The V do-
main has two N-glycosylation sites and is responsible for most
(but not all) extracellular ligand binding [4]. The cytoplasmic
tails are believed to be essential for intracellular signaling [5].
Althoughﬁrst described as a receptor forAGEs, the products
of non-enzymatic glycation and oxidation of proteins/lipids, la-
ter studies indicated that RAGE was also a signal transduction
receptor for pro-inﬂammatory S100/calgranulins, amphoterin
[or high mobility group box 1 (HMGB1)], amyloid peptide
and sheet ﬁbrils. Additionally, RAGE is a counter-receptor for
Mac-1. These ligands may be generated and accumulate in di-
verse settings such as diabetes, renal failure, neurodegeneration,
autoimmunity/inﬂammatory milieu, and aging [6].
RAGE, functions as a master switch that induces sustained
activation of nuclear factor-kappaB (NF-jB), suppresses a
series of endogenous auto regulatory functions and converts
long-lasting pro-inﬂammatory signals into sustained cellular dys-
functionanddisease. Its activation is associatedwithhigh levels of
dysfunctioning proteins in body ﬂuids and tissues, and strongly
associated with a series of diseases from allergy and Alzheimer
to rheumatoid arthritis and urogenital disorders [7].
As regards RA, RAGE is expressed by many of the cells
that participate in the development of RA, including macro-
phages, neutrophils and T cells. RAGE is expressed on macro-phages and T cells within synovial tissues of RA patients as
well as on synovial ﬂuid macrophages [8]. Synovial ﬁbroblasts
that account for about 50% of the cellular constituents of the
synovial lining layer constitutively also express RAGE [9].
Not only the RAGE but also its ligands have been investi-
gated in arthritis. One of the RAGE ligand HMGB1 is over ex-
pressed in inﬂammatory arthritis with a consequence of RAGE
binding resulting in macrophage stimulation, induction of
TNF-a and IL-6, maturation of DCs, Th1 cell responses, stim-
ulation of CD4+ and CD8+ cells, and ampliﬁcation of re-
sponse to local cytokines occurs [10].
Several RAGE ligands are characteristically overexpressed
in RA. High concentrations of three of its putative pro-inﬂam-
matory ligands, S100A8/A9 complex (calprotectin), S100A8,
and S100A12, are found in rheumatoid arthritis (RA) serum
and synovial ﬂuid [11].
RAGE binding to pro-inﬂammatory ligands, including
members of the S100/calgranulin family, and high mobility
group box chromosomal protein 1 (HMGB1), is implicated
in cell signaling by synergizing with DNA CpG motifs [12,13].
Soluble C-truncated RAGE (sRAGE) lacks the transmem-
brane and cytosolic domains of the full-length receptor, is a
secretory splice isoform which can prevent pro-inﬂammatory
effects of RAGE signaling by acting as a decoy by removal/
neutralization of circulating ligands [14].
Increasing the production of plasma sRAGE is therefore
considered to be a promising therapeutic target that has the
potential to prevent multiple diseases [15]. Clinical studies have
shown that higher plasma levels of sRAGE are associated with
a reduced risk of coronary artery disease [6], hypertension [16],
arthritis [17] and Alzheimer’s disease [18]. In a collagen-in-
duced arthritis (CIA) murine model, treatment with murine
sRAGE signiﬁcantly reduced joint inﬂammation and destruc-
tion [19]. It has previously been shown that a polymorphism
of the gene encoding RAGE located within the V-type immu-
noglobulin domain of RAGE, which results in a glycine to ser-
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librium with HLA-DR4 [20], it was therefore not surprising
that the Ser82 allele was increased in RA subjects [19].
It is conceivable that this, or other linked polymorphisms in
the RAGE gene affect splicing of the C-truncated, endoge-
nously secreted form of the receptor, or susceptibility to cell
surface RAGE cleavage by matrix metalloproteinase thus
altering the ratio of soluble to membrane RAGE [11].
The aim of this study is to evaluate the levels of sRAGE in RA
patients and to detect the gene polymorphism and to assess the
relationship between sRAGE levels and disease characteristics.
2. Patients and methods
The study included 33 patients (26 females and 7 males) with
RA who fulﬁlled the ACR criteria for diagnosis of RA [21].
All patients were recruited from the Rheumatology Depart-
ment, Cairo University Hospitals. Sixteen healthy normal sub-
jects with matched age and sex were enrolled as controls.
Informed consent was obtained from all subjects.
All patients were subjected to full assessment including:
1. History taking: especially for presenting symptoms, joint
affection, morning stiffness (MS), skin changes, Raynaud’s
phenomenon, gastrointestinal, pulmonary, cardiac, muscu-
loskeletal or neurological manifestations, together with his-
tory of medications.
2. General examination: especially for eye affection, head and
neck, extremities, skin, muscle, chest, cardiac and neurolog-
ical examination.
3. Locomotor examination: including tender joint count (TJC),
swollen joint count (STC) and estimation of disease activity
score DAS28-ESR [22].
4. Laboratory investigations:
4.1. Routine laboratory tests: complete blood picture
(CBC), erythrocyte sedimentation rate (ESR), urine
analysis, kidney function tests, liver function tests
and RF (by indirect ﬂuorescence technique).
4.2. Estimation of C-reactive protein (CRP) by turbidim-
etry [23].
2.1. Detection of sRAGE level
Soluble RAGE determination by enzymatic immunoassay by
kit supplied by R&D Systems (Minneapolis, MN, USA)
according to manufacturer recommendation [24].
2.2. Genotyping
Molecular study of single nucleotide polymorphisms (SNP) in
the glycine82serine (G82S) polymorphism of the RAGE gene
for genotypingwas done.GenomicDNAwas extracted and then
genotyped by polymerase chain reaction/restriction fragment
length polymorphism (PCR andRFLP). The affected exon con-
sidered was ampliﬁed by PCR and the products were digested
with appropriate restriction enzyme fragment were ﬁnally size
fractionated on agarose gel to allow allele assignment. DNA was
extracted fromwhole blood using DNA extraction kit (BioRad,
Italy) The average DNA concentration was determined by
absorbance at 260 nm using Perkin Elmer spectrophotometerand the integrity of the DNA was checked by electrophoresis
on 0.8% agarose gel with an ethidium bromide. The affected
exon considered was ampliﬁed by PCR in 50 ll reactionmixture
consisting of 67 mM Tris–HCl (pH 8.8), 1 mM magnesium
chloride, 10 mM dNTPs, 5 pmol of each primer – sense primer:
50-GTAAGCGGGGCTC- CTGTTGCA-30; antisense primer:
50-GGCCAAGGCTGGG-GTTGAAGG-30, 100 ng of extracted
DNA and 2.5 units of Taq DNA polymerase (Amersham Phar-
maciaBiotech.). PCRwas carried out in thermal cycler (Hybaid)
with 35 cycle of denaturation for 1 min at 94 C and annealing
for 1 min at 58 C and extension for 1 min at 72 C with ﬁnal
extension step 72 C for 10 min. To detect glycine82serine
(G82S) polymorphism of the RAGE gene, the PCR product
was then digested with Alu I (Life Technologies) restriction en-
zyme. For digestion 17 ll of PCR product, 2 ll of buffer and
10 ll of restriction endonuclease (10 unit/ll) were mixed and
incubated for 12 h at 37 C. Digested DNA product was sepa-
rated by electrophoresis in 2.5% agarose gel stained with ethi-
dium bromide and visualized by UV transilluminator [25].
2.3. Statistical analysis
Data were coded and entered using the statistical package
SPSS version 12. Data were summarized using mean and stan-
dard deviation for quantitative variables and percent for qual-
itative variables. Comparisons between groups were performed
using Chi-square test for qualitative variables and independent
sample t-test and analysis of variance (ANOVA) for normally
distributed quantitative variables. While non-parametric
Mann–Whitney test and Kruskal–Wallis test were used for
abnormally distributed quantitative variables. Correlation
was done to test for linear relations between quantitative vari-
ables. Linear regression analysis was done to ﬁnd signiﬁcant
predictors of sRAGE levels. In all cases p value <0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Basic demographic, clinical and laboratory data
The age of patients ranged between 20 and 66 years with a mean
of 45.44 ± 11.68 years. The age at disease onset ranged between
15 and 64 years with amean of 39.44 ± 11.31 years. The disease
duration (deﬁned as the interval in years between the appearance
of the ﬁrst manifestation related toRA and the time at which the
study started) extended between 1 and 18 years with a mean
of 6.0 ± 4.61 years. The morning stiffness time ranged from
0–5 h with a mean of 0.78 ± 1.09. Four patients were diabetics;
six were hypertensive, ﬁve patients with cardiac disease (ische-
mic heart disease) and three with chest disease (interstitial lung
ﬁbrosis). RF was positive in 24 patients (72.7%) and was nega-
tive in all controls. CRP was signiﬁcantly higher in RA patients
as compared with controls (4.71 ± 2.2 versus 2.11 ± 1.1,
p< 0.01). The DAS28-ESR mean was 3.38 ± 1.06.
3.2. Serum levels of sRAGE
We observed the decreased levels of serum sRAGE in RA pa-
tients than controls (840.11 ± 230.32 pg/ml versus 1111.59 ±
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Figure 1 sRAGE level in RA patients and controls. The serum
level of soluble receptor of advanced glycation end product was
statistically lower in patients with rheumatoid arthritis compared
to the control p< 0.05.
Table 1 Correlation between sRAGE level and clinical and
laboratory data of RA patients.
sRAGE
Pearson correlation (r) p value
Age (years) 0.021 0.908
Age at onset (years) 0.083 0.641
Disease duration (years) 0.159 0.368
MS (min) 0.572 0.001*
SJC 0.131 0.460
TJC 0.371 0.031*
DAS 28 0.278 0.112
Hb 0.242 0.197
CRP 0.633 0.000*
MS: Morning stiffness; SJC: swollen joint count; TJC: tender joint
count; DAS 28: disease activity score 28; Hb: hemoglobin; CRP:
C-reactive protein.
* Signiﬁcant correlation (p< 0.05).
56 A. Mokbel et al.143.20 pg/ml). The difference was signiﬁcantly lower as
p< 0.05. This is shown in Fig. 1.
3.3. Genotyping of the receptor of advanced glycation end
products
The results ofmolecular study for genotyping of theRAGEgene
showed polymorphisms in the glycine82serine (G82S) in 22 out
of 33 RA patients, 5 of them were homozygous for the RAGE
serine82 allele and 17 were heterozygous. Genotyping of the
RAGE gene in the control subjects showed polymorphisms in
the G82S in 5 out of 16, only one of them was homozygous for
the RAGE serine82 allele and the other four were heterozygous.
The difference in gene polymorphism between cases and con-
trols did not reach statistical signiﬁcant levels.
3.4. Correlation between sRAGE level, clinical and laboratory
data of RA patients
The sRAGE levels were signiﬁcantly lower in RA patients with
more disease activity as indicated by MS, TJC and CRP (p val-
ues were <0.05). This is shown in Table 1.
3.5. Studying the relation between sRAGE, RF and associated
extra-articular manifestations of RA patients
This showed that sRAGE levels were signiﬁcantly lower in RA
patients with Sjogren’s syndrome than those without this syn-
drome and in patients with cardiac disease. This is shown in
Table 2.
3.6. Signiﬁcant predictors for sRAGE level
Linear regression analysis was done to detect signiﬁcant pre-
dictors for sRAGE as shown in Table 3. The signiﬁcant predic-
tors found included CRP and gene polymorphism.
3.7. The relation between gene polymorphism and clinical and
laboratory data of RA patients
The glycine82serine (G82S) allele was related to MS, CRP
and sRAGE level. We did not identify correlationbetween gene polymorphism and any other data as shown in
Table 4.
3.8. The relation between gene polymorphism, RF and associated
extra-articular manifestations of RA patients
This showed that the glycine82serine (G82S) allele is more
common in patients with cardiac affection (Table 5).
4. Discussion
The results of the current study showed decreased serum levels
of sRAGE in a cohort of patients with RA than the normal
subjects and the levels were signiﬁcantly lower in RA patients
with more disease activity and in those who carried the poly-
morphisms in the glycine82serine (G82S) allele.
This was similar to Pullerits et al., who reported that the
plasma levels of sRAGE to be reduced in subjects with rheu-
matoid arthritis compared with healthy controls or subjects
with non-inﬂammatory joint disease. These ﬁndings suggest
the possibility that levels of sRAGE might be a biomarker of
inﬂammation [17].
The receptor for advanced glycation end products (RAGE)
interacts with distinct ligand families linked to the inﬂamma-
tory response. Studies in animal models suggest that RAGE
is up regulated in the inﬂamed joint and that blockade of the
receptor, using a ligand decoy soluble form of RAGE
(sRAGE), attenuates joint inﬂammation and expression of
inﬂammatory and tissue-destructive mediators [26].
In RA, there is a wide diversity of RAGE ligands present in
the inﬂamed joints, as well as in the circulation, that could lead
to the binding and consumption of sRAGE during the inﬂam-
matory process. One of the high-afﬁnity ligands for RAGE/
sRAGE is HMGB1, a potent cytokine playing an important
role in the pathogenesis of chronic inﬂammation. HMGB1 is
a potent trigger of arthritis and its expression is increased in
synovial tissue of RA patients as well as in experimental arthri-
tis [27]. HMGB1 levels in the synovial ﬂuid and sera of RA pa-
tients are signiﬁcantly elevated as compared with levels in
Table 2 Relation between sRAGE and RF and associated extra-articular manifestations of RA patients.
sRAGE No. (percent) Mean ± SD Student t-test
p value
RF +ve 24 (72.7%) 834.76 ± 257.80 0.47
ve 9 (27.3%) 903.28 ± 152.85
Extra-articular manifestations +ve 16 (48.5%) 838.07 ± 244.39 0.81
ve 17 (51.5%) 858.92 ± 228.31
SC nodules +ve 9 (27.3%) 904.19 ± 265.71 0.51
ve 24 (72.7%) 832.43 ± 224.79
Sjogren’s syndrome +ve 8 (24.2%) 830.65 ± 258.12 0.031*
ve 25 (75.8%) 906.09 ± 115.41
Chest aﬀection +ve 3 (9.1%) 916.34 ± 249.65 0.63
ve 30 (90.9%) 844.88 ± 235.43
Cardiac aﬀection +ve 5 (15.2%) 581.65 ± 210.18 0.01*
ve 28 (84.8%) 891.61 ± 192.51
Diabetes +ve 4 (12.1%) 847.68 ± 302.03 0.99
ve 29 (87.9%) 849.04 ± 226.90
Hypertension +ve 6 (18.2%) 834.40 ± 238.22 0.79
ve 27 (81.8%) 827.36 ± 241.73
RF: Rheumatoid factor; SC nodules: subcutaneous nodule.
* Signiﬁcant difference (p< 0.05).
Table 3 Linear regression analysis for signiﬁcant predictors of sRAGE.
Unstandardized coeﬃcients Standardized coeﬃcients
b
t Sig. 95% conﬁdence interval for B
B Std. Error
D.D. 3.108 6.167 .064 .504 .621 16.118 to 9.903
Extra-articular manifestations 12.888 93.858 .028 .137 .892 210.911 to 185.135
Sc nodules 35.775 91.277 .067 .392 .700 156.803 to 228.353
Sjogren’s 54.913 102.117 .103 .538 .598 160.535 to 270.361
Chest aﬀection 138.823 181.585 .111 .765 .455 244.287 to 521.934
Heart aﬀection 128.248 117.234 .194 1.094 .289 375.589 to 119.094
HTN 68.368 92.409 .103 .740 .469 126.597 to 263.334
Hb 13.607 21.682 .090 .628 .539 32.137 to 59.351
CRP 33.952 14.635 .309 2.320 .033* 64.830 to 3.074
RF 111.500 58.045 .218 1.921 .072 233.965 to 10.966
Gene polymorphism 223.839 57.639 .651 3.883 .001* 345.446 to 102.231
D.D.: Disease duration; Sc nodules: subcutaneous nodules; HTN: hypertension; Hb: hemoglobin; CRP: C-reactive protein; RF: rheumatoid
factor.
* Signiﬁcant negative predictor.
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may form in vivo complexes with HMGB1 in the sera/synovial
ﬂuid of RA patients, leading to inaccurately low levels of
sRAGE.
Other ligands such as S100A8/A9 (calprotectin) and
S100A12 (calgranulin C, EN-RAGE) levels are signiﬁcantly
elevated in serum and synovial ﬂuid from RA patients com-
pared to healthy normal donors [2,29]. S100A8/A9 levels are
also higher in supernatants of cultured RA synoviocytes than
of osteoarthritis synoviocytes [30]. Vyta´sˇek et al. reported the
increased level of speciﬁc glycation end products in sera of pa-
tients with rheumatoid arthritis [31].
The presence of high levels of these soluble ligands in RA
patients provides a basis for increased consumption of thesRAGE by interaction, followed by elimination of such
sRAGE–ligand complexes via the reticuloendothelial system
[32].
In our study, linear regression analysis showed that gly-
cine82serine (G82S) polymorphism in the RAGE gene to be
signiﬁcant predictor of the serum level of sRAGE which is sim-
ilar to Chen et al. who postulated that the polymorphism in the
RAGE gene at this site may cause altering the ratio of soluble
to membrane RAGE [11].
The current study showed that, there is signiﬁcant decrease
in levels of sRAGE with increased disease activity as indicated
by increased duration of MS, increased TJC and increased
CRP levels. Similarly Soluble RAGE levels were negatively
associated with serum levels of C-reactive protein (CRP) [11].
Table 4 Relation between gene polymorphism and clinical and laboratory data of RA patients (ANOVA).
Genotype No. (percent) Mean ± SD p value
Age 1 11 (33.3%) 46.00 ± 11.99 0.539
2 17 (51.5%) 46.61 ± 10.93
3 5 (15.2%) 40.01 ± 14.65
Age of onset 1 11 (33.3%) 39.55 ± 11.92 0.372
2 17 (51.5%) 41.17 ± 10.34
3 5 (15.2%) 33.00 ± 13.47
Disease duration 1 11 (33.3%) 6.36 ± 5.84 0.783
2 17 (51.5%) 5.50 ± 3.79
3 5 (15.2%) 7.00 ± 5.10
MS 1 11 (33.3%) 0.36 ± 0.35 0.048*
2 17 (51.5%) 0.79 ± 1.20
3 5 (15.2%) 1.90 ± 1.39
SJC 1 11 (33.3%) 3.27 ± 2.94 0.126
2 17 (51.5%) 4.61 ± 7.19
3 5 (15.2%) 7.40 ± 4.83
TJC 1 11 (33.3%) 8.00 ± 5.20 0.410
2 17 (51.5%) 10.94 ± 8.35
3 5 (15.2%) 14.60 ± 9.69
DAS 28-ESR 1 11 (33.3%) 3.13 ± 0.85 0.372
2 17 (51.5%) 3.36 ± 1.14
3 5 (15.2%) 3.95 ± 1.16
Hb 1 11 (33.3%) 10.59 ± 1.32 0.066
2 17 (51.5%) 11.53 ± 1.55
3 5 (15.2%) 12.50 ± 1.00
CRP 1 11 (33.3%) 3.72 ± 1.53 0.024*
2 17 (51.5%) 4.57 ± 2.15
3 5 (15.2%) 6.87 ± 2.51
sRAGE 1 11 (33.3%) 1030.96 ± 63.28 0.000*
2 17 (51.5%) 818.38 ± 168.59
3 5 (15.2%) 490.66 ± 197.57
MS: Morning stiffness; SJC: swollen joint count; TJC: tender joint count; DAS28-ESR: disease activity score 28-erythrocyte sedimentation rate;
Hb: hemoglobin; CRP: C-reactive protein; sRAGE: soluble receptor of advanced glycation end products.
* Signiﬁcant correlation.
58 A. Mokbel et al.Taken together the decrease in the level of sRAGE and the
association with markers of disease activity, it was suggested
that sRAGE may block the ligand–RAGE interaction on the
cell surface by directly binding leukocyte b2-integrin Mac-1
and thereby decreasing inﬂux of inﬂammatory cells into the
joint cavity, functioning as an immune surveillance mecha-
nism. Lower levels of sRAGE detected in RA patients might
thus increase the propensity towards inﬂammation since
RAGE ligands have better access to cell membrane-bound
receptor, the binding of which leads to the activation of inﬂam-
matory pathways. The treatment with methotrexate was
shown to counteract this pro-inﬂammatory feature in patients
with RA [17]. In our study we were not able to examine the ef-
fect of the medications as all our patients were receiving
methotrexate.
Our results showed that, there is decreased level of sRAGE
in RA patients with Sjogren’s syndrome than RA patients
without Sjogren’s syndrome. The immunohistochemical
expression and immunoblotting of RAGE in labial salivary
glands from Sjogren’s syndrome patients were investigated.RAGE is present in the labial salivary glands of both normal
and Sjogren’s syndrome, with preliminary data suggesting
over-expression in tissues from Sjogren’s syndrome patients
[33]. Further our results also showed that there is decreased le-
vel of sRAGE in RA patients with cardiac disease than those
without cardiac affection. Cardiovascular (CV) disease is in-
creased in patients with chronic inﬂammatory disease, includ-
ing RA. Furthermore it has become clear at a
pathophysiological level, that atherosclerosis has striking sim-
ilarities with autoimmune disease. The receptor for advanced
glycation end products (RAGE) has been identiﬁed as a candi-
date molecule inﬂuencing response to ongoing inﬂammation
and autoimmunity [34]. Soluble RAGE was found to be asso-
ciated not just with RA inﬂammation and autoantibody pro-
duction, but also with classical vascular risk factors for end-
organ damage [11]. Moreover in this study the gene polymor-
phism was also correlated to cardiovascular symptoms. Con-
sistent with its role as a RAGE decoy molecule, these data
suggested that RAGE activity inﬂuences co-development of
joint and vascular disease in rheumatoid arthritis patients.
Table 5 Relation between gene polymorphism and RF and extra-articular manifestations of RA patients (Chi-square).
Gene 1 No. Gene 2 No. Gene 3 No. p value
RF +ve 9 9 3 0.47
ve 2 6 1
Extra-articular manifestation +ve 4 7 3 0.48
ve 6 8 1
SC nodules +ve 3 3 1 0.84
ve 7 12 3
Sjogren’s syndrome +ve 1 5 1 0.4
ve 9 10 3
Chest aﬀection +ve 0 1 0 0.61
ve 10 14 4
Cardiac aﬀection +ve 0 2 2 0.04*
ve 10 13 2
Diabetes +ve 1 2 1 0.76
ve 9 13 3
Hypertension +ve 1 2 1 0.76
ve 9 13 3
RF: Rheumatoid factor; SC nodules: subcutaneous nodules.
* Signiﬁcant difference (p< 0.05).
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ment the study of non-diabetic men with and without coronary
artery disease showed lower levels of plasma sRAGE in these
subjects which correlated with the highest incidence of coro-
nary artery disease [35].
In contrary to our study Gly82Ser polymorphism in the
RAGE gene (RAGE 82Ser) occurred more frequently in RA
patients than in healthy controls [19]. In the current study
the comparison of the glycine82serine (G82S) polymorphism
between RA patients and healthy controls didn’t reach statis-
tical signiﬁcant levels. Larger group size may ﬁgure out this
difference.
In this study gene polymorphism is related to disease activ-
ity as indicated by MS and CRP in RA patients, in contrary to
others who did not ﬁnd any relation between the polymor-
phism and higher levels of inﬂammation [31].
The sRAGE levels were decreased in patients with rheuma-
toid arthritis than the healthy subjects and this decrease was
correlated with the gene polymorphism which may be a caus-
ative effect and it was also correlated with markers of disease
activity which may point to its protective role in the severity of
joint inﬂammation. The association found between the gene
polymorphism, the level of sRAGE and cardiovascular disease
suggested that RAGE activity inﬂuences co-development of
joint and vascular disease in rheumatoid arthritis patients.
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